Beta Drugs Limited has reported its financial results for the half year ending September 30, 2024, showing a 28% revenue growth to Rs 180.3 crores and a net profit increase of 23% to Rs 24.44 crores, with an EBITDA margin of 22.36%. The company anticipates revenue for FY25 to be between Rs 370 to 380 crores and aims to enhance its second-half performance.